As stated, we should prize success and not failures.
The outcome of the product validity for a topical product has shown their limits. Some members seat there from day 1 when the company was called Tissue Therapies. This company was listed in 2007.
At least let's be honest on this issue.
Errors were made.
Are they going to make it with a new biotech product? Are they capable to really build shareholders value?
FTT Price at posting:
0.4¢ Sentiment: None Disclosure: Held
